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What's new? 
 Using population-wide registers we describe contemporary trends in ischaemic stroke 
incidence and case fatality in people with and without a diagnosis of Type 2 diabetes.  
 Declines in ischaemic stroke incidence and case fatality have occurred at the same rate in 
people with and without a diagnosis of Type 2 diabetes, despite attempts to intensify 
cardiovascular disease risk factor control in people with diabetes.  
 Between 2004 and 2013, the prevalence of diagnosis of Type 2 diabetes in patients 
experiencing ischaemic stroke in Scotland increased from 13.5% to 20.3%.   
 
Abstract 
Aim To describe trends in first ischaemic stroke incidence and case fatality in adults with and 
without a diagnosis of Type 2 diabetes prior to their ischaemic stroke event in Scotland between 
2004 and 2013.  
Methods Using population-wide hospital admission, death and diabetes datasets, we conducted a 
retrospective cohort study. Negative binomial and logistic regression models were used to calculate 
year-specific incidence and case-fatality rates for people with Type 2 diabetes and for people 
without diabetes.  
Results During 41.0 million person-years of follow-up there were 69 757 ischaemic stroke events. 
Type 2 diabetes prevalence among patients who experienced ischaemic stroke increased from 13.5% 
to 20.3% between 2004 and 2013. Stroke incidence rates declined by 2.7% (95% CI 2.4, 3.0) annually 
for people with and without diabetes [diabetes/year interaction: rate ratio  0.99 (95% CI 0.98, 1.01)]. 
Type 2 diabetes was associated with an increased risk of ischaemic stroke in men [rate ratio 1.23 
(95% CI 1.17, 1.30)] and women [rate ratio 1.41 (95% CI 1.35, 1.48)]. Case-fatality rates were 14.2% 
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and 12.7% in people with Type 2 diabetes and without diabetes, respectively. Case fatality declined 
by 3.5% (95% CI 2.7, 4.5) annually [diabetes/year interaction: odds ratio 1.01 (95% CI 0.98, 1.02)].  
Conclusions Ischaemic stroke incidence declined no faster in people with a diagnosis of Type 2 
diabetes than in people without diabetes. Increasing prevalence of Type 2 diabetes among stroke 
patients may mean that declines in case fatality over time will be less marked in the future. 
 
Introduction 
Ageing populations, increasing obesity prevalence and improved survival have contributed to 
increasing Type 2 diabetes prevalence in developed countries [1]. Type 2 diabetes is an important 
cause of cardiovascular disease; ischaemic stroke, for example, is >1.5 times more common in 
people with diabetes than in similar populations without diabetes [2].  
It is not known, however, whether recent improvements in the management and treatment of 
cardiovascular risk factors has reduced this excess risk of stroke in people with diabetes [3,4]. The 
overall incidence of ischaemic stroke is estimated to have declined by 13% in high-income countries 
between 1980 and 2010 [5], but it is unclear whether people with Type 2 diabetes have experienced 
similar benefits.  
Scotland maintains a national register of all people with Type 2 diabetes, and this register is linked to 
population-based hospitalization and mortality registers. Using these large, robust population-wide 
databases, we have compared trends in ischaemic stroke incidence and case fatality in men and 
women with a diagnosis of Type 2 diabetes and in the population of people without diabetes in 
Scotland between 2004 and 2013.  
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Methods 
Data sources 
Mid-year population estimates by age, sex and decile of socio-economic status were obtained from 
the National Records of Scotland. Socio-economic status was defined using the 2012 version of the 
Scottish Index of Multiple Deprivation, an area-based measure of deprivation which uses 
information from seven domains, including income, employment, crime and education, to assign 
deprivation scores to 6505 small area-zones in Scotland (see 
http://www.gov.scot/Topics/Statistics/SIMD for further information). 
Ischaemic stroke was defined as any hospital admission or death in which the primary diagnosis or 
cause of death was assigned a 10th revision of International Classification of Diseases (ICD-10) code 
of I63 and I64. Admission and death data were obtained from the National Records of Scotland 
death registrations and the national hospitalization register (Scottish Morbidity Record, SMR01), 
respectively. The SMR01 is a population-based register of hospital admission episodes occurring in 
Scotland, and holds information on patient conditions leading to admission. Unspecified strokes 
(ICD-10 I64) were included in the main analyses because the majority of these events are likely to be 
ischaemic stroke events, but sensitivity analyses were conducted in which unspecified strokes were 
excluded. A look-back period of 10 years was used to exclude previous stroke events, identified 
using the previously defined ICD-10 codes and the following ICD-9 codes: 433, 434 and 436. This 
look-back period is consistent with the definition of incident ischaemic stroke events in data 
published by the Information Services Division, Scotland. It ensures a consistent look-back period for 
all individuals, which is important because electronic records only go back to 1981 and lifetime data 
are not available. Case fatality was defined as a death within 30 days of a hospital admission with 
ischaemic stroke.  
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Type 2 diabetes status was ascertained by linkage to a research extract of the Scottish Care 
Information – Diabetes dataset. This national register collates demographic and clinical data from 
primary and secondary care clinics in Scotland. Since 2004, this register has covered >99.5% of 
people with a diagnosis of diabetes in Scotland. For research purposes, an algorithm, which uses 
clinician-recorded diagnosis, prescription data and age at diabetes diagnosis, was used to ascertain 
diabetes type. Presence of Type 2 diabetes was defined for the present study on the basis of a 
diagnosis of Type 2 diabetes prior to hospital admission or death from ischaemic stroke.  
Approval for generation and analysis of the linked dataset was obtained from the Caldicott guardians 
of all health boards in Scotland, the Privacy Advisory Committee of the Information Services Division 
of NHS National Services Scotland and the national multi-centre research ethics committee. 
Statistical analyses 
Analyses were conducted in people without a history of stroke, aged between 18 and 89 years, and 
who had available data on socio-economic status. The study group consisted of individuals with a 
diagnosis of Type 2 diabetes and a comparison group of individuals without a record of any type of 
diabetes prior to the ischaemic stroke event. To calculate the event numbers and person-time for 
people without diabetes, the number of incident stroke events and person-time at risk for the 
population of people with any type of diabetes were subtracted from the total number of events 
and person-time for the whole population (Fig. S1). The start and end dates were 1 January 2004 and 
31 December  2013, respectively. Individual person-time was estimated as the number of days 
between study start date (or date of diabetes diagnosis if diagnosis occurred during the study 
period) until date of incident event, death or study end date. 
Negative binomial regression models were used to estimate incidence rates and rate ratios by age, 
sex, calendar year, diabetes status and deprivation. Age in years was divided by 10 so that each 
increment was a decade. Deprivation decile 1 represented the most deprived group and deprivation 
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decile 10 represented the least deprived group. Calendar year was included in the models as a linear 
term. To investigate whether differential changes in ischaemic stroke risk had occurred in people 
with Type 2 diabetes and the comparison group, the final model included a two-way interaction 
term for calendar year and diabetes status. A three-way interaction term between sex, calendar year 
and diabetes status was also included to investigate whether the risk of ischaemic stroke was greater 
in women than in men with Type 2 diabetes and whether this relationship had changed over time. 
All other interaction terms between age, sex, deprivation, calendar year and deprivation were 
included if the exponentiated coefficient was ≥ 1.05 or ≤ 0.95.  
Logistic regression models were used to model case fatality by year, sex and diabetes status. For 
illustration, incidence and case fatality rates are presented for men and women aged 70 years in 
deprivation decile 5. 
Statistical analyses were conducted in R, version 3.2.2   
Results 
Overall, 69 757 ischaemic/unspecified stroke events occurred during 41.0 million person-years of 
follow-up. Of these events, 36 276 were coded specifically as ischaemic stroke. Among people with a 
pre-existing diagnosis of Type 2 diabetes there was a total of 11 437 ischaemic/unspecified stroke 
events during 1.9 million person-years. Table 1 shows the total number of ischaemic/unspecified 
stroke events by year, sex and diabetes status. Briefly, among patients who experienced ischaemic 
stroke, the proportion of people with Type 2 diabetes increased from 13.5% in 2004 to 20.3% in 
2013. Overall, the proportion of people dying within 30 days of hospital admission declined from 
13.8% to 10.7%. Crude case fatality was higher among people with Type 2 diabetes than in people 
without diabetes (14.2% vs 12.7%) and in women compared with men (14.9% vs 10.9%).  
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In models adjusted for age, sex and deprivation and diabetes, ischaemic/unspecified stroke 
incidence rates declined by 2.7% (95% CI 2.4, 3.0) each year overall. Rates of decline were similar in 
people with Type 2 diabetes to those without diabetes [rate ratio per year for interaction between 
diabetes and year 0.99 (95% CI 0.98, 1.01); P=0.91]. Incidence rates were higher for men than 
women and in people with Type 2 diabetes than in people without diabetes (Fig.1). Overall, the rate 
ratios for the association between Type 2 diabetes and ischaemic/unspecified stroke risk for the 
whole study period were 1.41 (95% CI 1.35, 1.48) for women and 1.23 (95% CI 1.17, 1.30) for men. 
The rate ratios for the association between Type 2 diabetes and ischaemic stroke were 1.43 (95% CI 
1.33, 1.53) and 1.42 (95% CI 1.33, 1.52) in women in 2004 and 2013, respectively. In men, the rate 
ratios were 1.28 (95% CI 1.20, 1.37) in 2004 and 1.21 (95% CI 1.13, 1.30) in 2013. Type 2 diabetes 
was associated with higher rate ratios in women than men (rate ratio for diabetes/sex interaction 
1.15 (95% CI 1.09, 1.27); P <0.001) and this effect did not change during the study period (rate ratio 
for diabetes/sex/year interaction 1.01 (95% CI 0.99, 1.02); P = 0.472). After stratification by age, sex 
differences in risk of incident ischaemic stroke were most apparent in people aged <60 years (Fig. 
S2).  
When ischaemic stroke deaths prior to hospital admission were excluded, Type 2 diabetes was 
associated with an increased risk of ischaemic stroke in men [rate ratio 1.26 (95% CI 1.20, 1.33)] and 
women [rate ratio 1.45 (95% CI 1.37, 1.52)].  
Case fatality at 30 days declined in relative terms by 3.6% per year (95% CI 2.7, 4.5) in the study 
population and there was no significant difference in rates of decline by Type 2 diabetes status 
[diabetes/year interaction: odds ratio 1.01 (95% CI 0.98, 1.02); P= 0.58 (Fig. 2)]. Case fatality was 
higher for people with Type 2 diabetes than in people without diabetes [age and deprivation 
adjusted odds ratio 1.18 (95% CI 1.09, 1.29) for women and 1.15 (95% CI 1.05, 1.26) for men].  
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Sensitivity analyses 
When unspecified stroke events (ICD-10 code I64; n=33 481, 48.0%) were excluded from the 
analyses, the findings were similar to the primary analyses (Table S1, Figs S3 and S4). Incidence rates 
of ischaemic stroke declined by 1.26% (95% CI 0.66, 1.87) per year in people with Type 2 diabetes 
and in people without diabetes [diabetes/year interaction: rate ratio 0.99 (95% CI 0.98, 1.01); P= 
0.91]. Overall, Type 2 diabetes conferred a 40.5% (95% CI 31.2, 50.2) and 19.2% (95% CI 11.7, 27.3) 
excess risk of ischaemic stroke among women and men with Type 2 diabetes compared with people 
without diabetes.  
Discussion 
Despite major initiatives to improve cardiovascular risk factors in people with Type 2 diabetes, 
ischaemic stroke incidence rates between 2004 and 2013 in people with a diagnosis of Type 2 
diabetes in Scotland fell no faster than those in the general population [6,7]. This trend and the 
growing prevalence of Type 2 diabetes means that one-fifth of people who have an ischaemic stroke 
now have Type 2 diabetes, a trend which is likely to have important implications for reductions in 
ischaemic stroke case fatality in years to come.  
As has been shown elsewhere, incidence rates of stroke in people with and without diabetes 
continued to decline between 2004 and 2013, reflecting improved treatment of hypertension and 
dyslipidaemia, as well as population-wide improvements in dietary salt intake and smoking 
prevalence [8,9]. Despite these improvements, Type 2 diabetes continues to confer an excess risk of 
ischaemic stroke, and this study indicates that the excess risk has remained unchanged.  
In the present study, Type 2 diabetes was associated with a 45% and 26% increased risk of hospital 
admission for ischaemic stroke in women and men, respectively. This represents a considerably 
smaller excess risk than observed in previous studies [2,10]. For example, in one study based on data 
from England, Type 2 diabetes was associated with a 3.5-fold increased risk of hospital admission for 
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stroke between 2004 and 2009 [10]. The discrepancy in strength of association may be partly 
explained by the exclusion of stroke deaths which occurred prior to hospital admission from the 
analyses presented in the English study. These deaths accounted for 11.7% and 13.8% of stroke 
events in people with and without a diagnosis of diabetes respectively in our data. Few other studies 
have presented contemporary trends in the association between Type 2 diabetes and ischaemic 
stroke, and comparisons are difficult because of differences in definitions of stroke and diabetes. For 
example, in the USA, the relative risk of stroke associated with diabetes declined from 2.5 (95% CI 
2.2, 2.7) in 2000 to 1.5 (95% CI 1.1, 2.0) in 2010, but this study did not distinguish between Type 1 
and Type 2 diabetes, nor were estimates provided for stroke subtypes [3].  
In an effort to improve health outcomes of people with chronic diseases such as Type 2 diabetes, the 
UK implemented the Quality and Outcomes Framework in 2004. This initiative incentivized general 
practices to reach a series of targets in the clinical management of chronic diseases and was 
expected to improve health outcomes for people with diabetes relative to the general population. 
Between 2004 and 2013, smoking prevalence declined and the management of hypertension, 
cholesterol and hyperglycaemia improved in people with Type 2 diabetes [11]. In addition it appears 
that diabetes may be being diagnosed earlier over time based on declining prevalence of retinopathy 
soon after diagnosis, perhaps as a result of wider diabetes screening [12]. While similar data for 
secular trends in cardiovascular disease risk factors in the Scottish population as a whole are limited, 
it is apparent that rates of obesity and hypertension have remained higher among people with Type 
2 diabetes compared with the general population [13]. For example, 63% of the Scottish adult 
population were overweight or obese in 2014, compared with 87% of adults with Type 2 diabetes in 
2014 [11,14]. Therefore, despite some improvements, people with Type 2 diabetes continue to have 
worse cardiovascular disease risk factor profiles than people without diabetes and subsequently 
remain at considerably greater risk of ischaemic stroke.  
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Consistent with previous findings, Type 2 diabetes had a greater relative influence on ischaemic 
stroke relative risk in women than men and this sex difference did not change considerably over 
time in the present study. A recent large meta-analysis reported a 27% higher relative risk of stroke 
for the effect of diabetes in women compared with men [15]; however, this relative risk ratio 
became only borderline significant after exclusion of haemorrhagic stroke [relative risk ratio 1.25 
(95% CI 1.01–1.54)] and when studies in which baseline data were collected before 1985 were 
excluded [relative risk ratio 1.21 (95% CI 1.01, 1.46)]. Similar non-significant sex differences in risk of 
stroke were also observed in the Clinical Practice Research Datalink database and the General 
Practice Research Database in the UK [2,16]. In both studies the sex difference was more apparent 
among people aged <60 years, a finding that we have replicated here (Fig. S2).  
Several explanations for the sex difference in diabetes-related excess risk of stroke have been 
proposed [17]. Firstly, while women in the general population usually have more favourable 
cardiovascular disease risk profiles than men, women exhibit greater deteriorations in cardiovascular 
disease risk profiles with the development of diabetes than men. For example, two UK-based studies 
have shown that men typically have lower BMI at diagnosis of Type 2 diabetes than women, 
suggesting that women need to gain more weight to develop diabetes than men, and this is 
particularly marked at younger ages of diagnosis [18,19]. Furthermore, several studies have shown 
that the relative difference in levels of cardiovascular disease risk factors, including levels of insulin 
resistance, lipids, fibrinogen and diastolic blood pressure between people with and without diabetes 
is greater in women than men [20–22].  
Secondly, differences in diabetes management may also contribute to this sex difference, with some 
evidence to suggest that women with Type 2 diabetes are less likely than men to be prescribed 
statins, anti-hypertensive agents and β-blockers  [17,23]. Similarly, in a cross-sectional study 
consisting of 10 191 people with Type 2 diabetes in Tayside, Scotland, women were less likely to 
have their cholesterol or blood pressure recorded than men [24].  
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Thirdly, poor glucose control may have a more adverse effect on women than men in terms of stroke 
risk [25].  
Finally, even when treated similarly, women with Type 2 diabetes have been shown to be less likely 
to achieve cardiovascular disease risk factor targets than men [24,26–28]. In Scotland, women with 
diabetes were less likely to achieve all four targets for HbA1c, cholesterol, blood pressure and 
smoking cessation than men [odds ratio 0.75 (95% CI 0.67, 0.84)] [24]. Accordingly, women with 
Type 2 diabetes appear to have a greater cardiovascular risk factor burden compared with their 
counterparts without diabetes, emphasizing a greater requirement for more aggressive risk factor 
monitoring and treatment in women with diabetes.  
Despite this sex difference in relative risks, fatal and non-fatal stroke events are more common in 
men than women after adjusting for age and deprivation, regardless of diabetes status. 
Improvements in primary and secondary prevention in both men and women prior to and after 
diabetes diagnosis should therefore remain a priority.  
Our findings of proportionately more patients with stroke having diabetes (now one in five at stroke 
presentation) are relevant to primary and secondary prevention of stroke. Notably, recent 
randomized controlled trials show that some of the newer diabetes therapies (e.g. the glucagon-like 
peptide-1 receptor agonist semaglutide, not yet licensed) may be associated with reduced stroke 
risk in people with diabetes [29], while pioglitazone may provide survival benefits post-stroke in 
patients with insulin resistance [30]. Further research is therefore required to determine to what 
extent more recent diabetes therapies can lower the risk of stroke or improve survival post-stroke.   
The present study used population-based data to provide contemporary, long-term estimates which 
are representative of the entire Scottish population. Diabetes status was ascertained using the 
National Diabetes Register rather than through hospital admission databases which have been 
shown to under-report diabetes cases [31].  
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Unlike many previous studies which have been unable to distinguish between Type 1 and Type 2 
diabetes, we were able to provide estimates for ischaemic stroke risk specifically for people with 
Type 2 diabetes. Significant differences in the aetiology, diagnosis and treatment of Type 1 and Type 
2 diabetes are likely to contribute to considerable differences in stroke risk which would have been 
masked by combining these conditions. Furthermore, diabetes status is validated in the diabetes 
register using an algorithm which uses prescription and age at diagnosis data [32]. The risk of 
misclassifying Type 1 diabetes cases as Type 2 diabetes is therefore minimized.  
The present study also has some limitations. There are likely to be inaccuracies in the coding of the 
event of interest because these are routinely recorded data. For example, a recent study identified 
that 25% of stroke events identified in the Scottish Stroke Care Audit were not recorded in the 
SMR01 dataset in 2010 [33]. Unidentified strokes in the SMR01 dataset are likely to have occurred 
through errors in the coding of primary diagnoses by coders and therefore, while this represents a 
significant proportion of stroke events, it seems unlikely that the recording of these events differed 
systematically by diabetes status.  
The lack of availability of clinical data for the population of people without diabetes prevented any 
further analyses of differences in cardiovascular disease risk factors by diabetes status to explain the 
observed trends. Furthermore, the duration of diabetes is likely to be a relevant risk factor for stroke 
in people with diabetes, but this was not explored in the present analyses. 
Finally, some people with diabetes that is first diagnosed during their stroke admission will have 
been included in the population without diabetes. This misclassification may have led to the 
underestimation of the strength of the association between Type 2 diabetes and ischaemic stroke, 
although it is uncertain whether this would also have affected whether the association between 
Type 2 diabetes and ischaemic stroke varied over time. 
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In conclusion, during the 10-year period between 2004 and 2013, stroke incidence declined 
regardless of diabetes status but risk of stroke remained 29–39% higher among people with a 
diagnosis of Type 2 diabetes than in the population of people without diabetes, despite significant 
efforts to improve cardiovascular disease risk factor management in people with Type 2 diabetes. 
The relative effect of Type 2 diabetes on stroke risk was higher in women but absolute risk was 
higher in men, indicating that primary and secondary prevention of both diabetes and ischaemic 
stroke are important in both sexes. Given the rising prevalence of diabetes in patients who 
experience stroke, further research investigating the effect of modern diabetes therapies on stroke 
incidence and case fatality are warranted.  
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Supporting information 
 
Additional Supporting Information may be found in the online version of this article:  
 
Table S1  Rate ratios of incident ischaemic stroke (I63) in people with Type 2 diabetes compared to 
people without diabetes in Scotland between 2004 and 2013. Estimates adjusted for age, 
deprivation status and year/deprivation interaction 
Figure S1. Three modes by which individuals contribute person-time to study. Participants were 
followed up until the first of ischaemic stroke event date, death or study end-point.  
Figure S2. Rate ratios of incident ischaemic stroke (I63, I64) in people with Type 2 diabetes 
compared to people without diabetes in Scotland between 2004 and 2013, stratified by sex and age 
(60 years, >60 years). Estimates are presented for deprivation decile 5. 
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Figure S3. Incidence rates of ischaemic stroke after excluding unspecified stroke events per 100,000 
for women and men with Type 2 diabetes and without diabetes between 2004 and 2013. The lines 
represent predicted incidence rates for men and women aged 70 years in deprivation decile 5.  
Figure S4. Case fatality (%) following incident ischaemic stroke [excluding unspecified stroke events 
(I64)] for women and men with Type 2 diabetes and without diabetes between 2004 and 2013. The 
lines represent predicted case fatality for men and women aged 70 years and in deprivation decile 5. 
 
FIGURE 1 Incidence rates of ischaemic stroke (International Classification of Disease-10 codes: I63, 
I64) per 1000 person-years for (a) women and (b) men with Type 2 diabetes and without diabetes 
between 2004 and 2013. Lines represent predicted incidence rates for men and women aged 70 
years and in deprivation decile 5. Model adjusted for the following interactions: sex/diabetes; 
sex/deprivation; deprivation/diabetes (P values all <0.001). 
FIGURE 2 Case fatalities (%) after incident stroke for (a) women and (b) men with Type 2 diabetes 
and without diabetes between 2004 and 2013. Lines represent predicted case fatality for men and 
women aged 70 years and in deprivation decile 5. 
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Table 1 Total number of stroke events (I63, I64), case fatality and person-time at risk for people aged 18–89 years, by diabetes status, sex and year in 
Scotland between 2004 and 2013  
 
Year 
Female  Male 
Population without diabetes Type 2 diabetes  Population without diabetes Type 2 diabetes 
Total 
events 
Case fatalities (% 
of hospital 
admissions) 
Person-
years, 
1000 
Total 
events 
Case fatalities (% 
of hospital 
admissions) 
Person-
years, 1000 
 
Total 
events 
Case fatalities (% 
of hospital 
admissions) 
Person-
years, 
1000 
Total 
events 
Case fatalities (% 
of hospital 
admissions) 
Person-
years, 
1000 
2004 3550 468 (16.0) 2016 505 73 (16.4) 65  3026 312 (11.8) 1804 525 45 (9.6) 76 
2005 3358 420 (14.8) 2026 516 79 (17.4) 70  2903 326 (12.6) 1815 564 74 (14.9) 82 
2006 3130 411 (15.5) 2034 507 75 (16.5) 75  2936 314 (12.1) 1827 509 59 (12.9) 88 
2007 2994 401 (15.8) 2046 485 75 (17.6) 79  2696 274 (11.4) 1842 535 68 (14.1) 94 
2008 3114 439 (16.5) 2056 499 83 (20.2) 82  2850 298 (11.7) 1855 586 78 (14.9) 99 
2009 3049 380 (14.4) 2064 567 90 (18.3) 87  2755 254 (10.1) 1865 622 60 (10.3) 105 
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2010 2975 364 (13.9) 2075 577 77 (15.2) 90  2701 258 (10.5) 1877 610 64 (11.5) 111 
2011 2856 338 (13.3) 2088 533 71 (15.3) 94  2673 210 (8.6) 1894 639 81 (13.8) 116 
2012 2737 312 (13.0) 2092 620 85 (15.5) 97  2650 214 (8.7) 1896 668 73 (11.6) 121 
2013 2737 310 (13.0) 2094 635 75 (13.4) 100  2630 198 (8.2) 1901 735 68 (10.0) 127 
Total 30500 3843 (14.7) 20590 5444 783 (16.5) 838  27820 2658 (10.6) 18577 5993 670 (12.3) 1020 
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